Kaustav Majumder1, Arjun Gupta2, Nivedita Arora1, Preet Paul Singh3, Siddharth Singh4. 1. Department of Surgery, University of Minnesota, Minneapolis, Minnesota. 2. Department of Medicine, University of Texas Southwestern Medical Center, Dallas, Texas. 3. Division of Medical Oncology, Washington University School of Medicine, St Louis, Missouri. 4. Division of Gastroenterology, University of California, La Jolla, California. Electronic address: sis040@ucsd.edu.
Abstract
BACKGROUND & AIMS: Obesity is associated with an increased risk for pancreatic cancer, but it is unclear whether it affects mortality. We performed a systematic review and meta-analysis to assess the association between premorbid obesity and mortality from pancreatic cancer. METHODS: We performed a systematic search through January 2015 and identified studies of the association between premorbid obesity (at least 1 year prior to pancreatic cancer diagnosis) and pancreatic cancer-related mortality. We estimated summary adjusted hazard ratio (aHR) with 95% confidence interval (CI), comparing data from obese (body mass index [BMI] ≥30 kg/m(2)) and overweight subjects (BMI, 25.0-29.9 kg/m(2)) with those from individuals with a normal BMI (controls) by using random-effects model. RESULTS: We identified 13 studies (including 3 studies that pooled multiple cohorts); 5 studies included only patients with pancreatic cancer, whereas 8 studies evaluated pancreatic cancer-related mortality in cancer-free individuals at inception. In the meta-analysis, we observed increase in pancreatic cancer-related mortality among overweight (aHR, 1.06; 95% CI, 1.02-1.11; I(2) = 0) and obese individuals (aHR, 1.31; 95% CI, 1.20-1.42; I(2) = 43%), compared with controls; the association remained when we analyzed data from only subjects with pancreatic cancer. Each 1 kg/m(2) increase in BMI was associated with 10% increase in mortality (aHR, 1.10; 95% CI, 1.05-1.15) with minimal heterogeneity (I(2) = 0). In the subgroup analysis, obesity was associated with increased mortality in Western populations (11 studies; aHR, 1.32; 95% CI, 1.22-1.42) but not in Asia-Pacific populations (2 studies; aHR, 0.98; 95% CI, 0.76-1.27). CONCLUSIONS: In a systematic review and meta-analysis, we associated increasing level of obesity with increased mortality in patients with pancreatic cancer in Western but not Asia-Pacific populations. Strategies to reduce obesity-induced metabolic abnormalities might be developed to treat patients with pancreatic cancer.
BACKGROUND & AIMS:Obesity is associated with an increased risk for pancreatic cancer, but it is unclear whether it affects mortality. We performed a systematic review and meta-analysis to assess the association between premorbid obesity and mortality from pancreatic cancer. METHODS: We performed a systematic search through January 2015 and identified studies of the association between premorbid obesity (at least 1 year prior to pancreatic cancer diagnosis) and pancreatic cancer-related mortality. We estimated summary adjusted hazard ratio (aHR) with 95% confidence interval (CI), comparing data from obese (body mass index [BMI] ≥30 kg/m(2)) and overweight subjects (BMI, 25.0-29.9 kg/m(2)) with those from individuals with a normal BMI (controls) by using random-effects model. RESULTS: We identified 13 studies (including 3 studies that pooled multiple cohorts); 5 studies included only patients with pancreatic cancer, whereas 8 studies evaluated pancreatic cancer-related mortality in cancer-free individuals at inception. In the meta-analysis, we observed increase in pancreatic cancer-related mortality among overweight (aHR, 1.06; 95% CI, 1.02-1.11; I(2) = 0) and obese individuals (aHR, 1.31; 95% CI, 1.20-1.42; I(2) = 43%), compared with controls; the association remained when we analyzed data from only subjects with pancreatic cancer. Each 1 kg/m(2) increase in BMI was associated with 10% increase in mortality (aHR, 1.10; 95% CI, 1.05-1.15) with minimal heterogeneity (I(2) = 0). In the subgroup analysis, obesity was associated with increased mortality in Western populations (11 studies; aHR, 1.32; 95% CI, 1.22-1.42) but not in Asia-Pacific populations (2 studies; aHR, 0.98; 95% CI, 0.76-1.27). CONCLUSIONS: In a systematic review and meta-analysis, we associated increasing level of obesity with increased mortality in patients with pancreatic cancer in Western but not Asia-Pacific populations. Strategies to reduce obesity-induced metabolic abnormalities might be developed to treat patients with pancreatic cancer.
Authors: Traci N Bethea; Cari M Kitahara; Jennifer Sonderman; Alpa V Patel; Chinonye Harvey; Synnøve F Knutsen; Yikyung Park; Song Yi Park; Gary E Fraser; Eric J Jacobs; Mark P Purdue; Rachael Z Stolzenberg-Solomon; Elizabeth M Gillanders; William J Blot; Julie R Palmer; Laurence N Kolonel Journal: Cancer Epidemiol Biomarkers Prev Date: 2014-07-13 Impact factor: 4.254
Authors: Chen Yuan; Ying Bao; Chen Wu; Peter Kraft; Shuji Ogino; Kimmie Ng; Zhi Rong Qian; Douglas A Rubinson; Meir J Stampfer; Edward L Giovannucci; Brian M Wolpin Journal: J Clin Oncol Date: 2013-10-21 Impact factor: 44.544
Authors: Joao Incio; Josh Tam; Nuh N Rahbari; Priya Suboj; Dan T McManus; Shan M Chin; Trupti D Vardam; Ana Batista; Suboj Babykutty; Keehoon Jung; Anna Khachatryan; Tai Hato; Jennifer A Ligibel; Ian E Krop; Stefan B Puchner; Christopher L Schlett; Udo Hoffmman; Marek Ancukiewicz; Masabumi Shibuya; Peter Carmeliet; Raquel Soares; Dan G Duda; Rakesh K Jain; Dai Fukumura Journal: Clin Cancer Res Date: 2016-02-09 Impact factor: 12.531
Authors: Sobeyda B Gomez-Chou; Agnieszka Katarzyna Swidnicka-Siergiejko; Niharika Badi; Myrriah Chavez-Tomar; Gregory B Lesinski; Tanios Bekaii-Saab; Matthew R Farren; Thomas A Mace; Carl Schmidt; Yan Liu; Defeng Deng; Rosa F Hwang; Liran Zhou; Todd Moore; Deyali Chatterjee; Huamin Wang; Xiaohong Leng; Ralph B Arlinghaus; Craig D Logsdon; Zobeida Cruz-Monserrate Journal: Cancer Res Date: 2017-03-01 Impact factor: 12.701
Authors: Arjun Gupta; Avash Das; Kaustav Majumder; Nivedita Arora; Helen G Mayo; Preet P Singh; Muhammad S Beg; Siddharth Singh Journal: Am J Clin Oncol Date: 2018-09 Impact factor: 2.339
Authors: Kasper A Overbeek; Djuna L Cahen; Marcia Irene Canto; Marco J Bruno Journal: Best Pract Res Clin Gastroenterol Date: 2016-11-05 Impact factor: 3.043
Authors: Marco Gallo; Valerio Adinolfi; Viola Barucca; Natalie Prinzi; Valerio Renzelli; Luigi Barrea; Paola Di Giacinto; Rosaria Maddalena Ruggeri; Franz Sesti; Emanuela Arvat; Roberto Baldelli; Emanuela Arvat; Annamaria Colao; Andrea Isidori; Andrea Lenzi; Roberto Baldell; M Albertelli; D Attala; A Bianchi; A Di Sarno; T Feola; G Mazziotti; A Nervo; C Pozza; G Puliani; P Razzore; S Ramponi; S Ricciardi; L Rizza; F Rota; E Sbardella; M C Zatelli Journal: Rev Endocr Metab Disord Date: 2020-10-06 Impact factor: 6.514